Combined Metabolic Activators Accelerates Recovery in Mild‐to‐Moderate COVID‐19

Advanced Science

Jens Nielsen¹  Levent Doganay²  Mehtap Aydın³  Oktay Olmuscelik⁴  Hasan Turkez⁵  Gizem Dinler‐Doganay⁶  Jan Borén⁷  Dogukan Akyol⁸  Gizem Alkurt⁸  Adil Mardinoglu⁹  Woonghee Kim⁹  Xiangyu Li⁹  Mathias Uhlén⁹  Saeed Shoaie⁹  Muhammad Arif⁹  Cheng Zhang⁹  Ozlem Altay⁹  Hong Yang⁹ 

[1] Department of Biology and Biological Engineering Chalmers University of Technology Gothenburg SE‐41296 Sweden;Department of Gastroenterology Umraniye Training and Research Hospital University of Health Sciences Istanbul 34766 Turkey;Department of Infectious Diseases Umraniye Training and Research Hospital University of Health Sciences Istanbul 34766 Turkey;Department of Internal Medicine Istanbul Medipol University Bagcılar Istanbul 34214 Turkey;Department of Medical Biology Faculty of Medicine Atatürk University Erzurum 25240 Turkey;Department of Molecular Biology and Genetics Istanbul Technical University Istanbul 34469 Turkey;Department of Molecular and Clinical Medicine University of Gothenburg and Sahlgrenska University Hospital Gothenburg Gothenburg SE‐41345 Sweden;Genomic Laboratory (GLAB) Umraniye Training and Research Hospital University of Health Sciences Istanbul 34766 Turkey;Science for Life Laboratory KTH—Royal Institute of Technology Stockholm SE‐100 44 Sweden;

关键词: combined metabolic activators;    COVID‐19;    metabolomics;    omics data;    proteomics;   

DOI  :  10.1002/advs.202101222

来源: DOAJ

【 摘 要 】

Abstract COVID‐19 is associated with mitochondrial dysfunction and metabolic abnormalities, including the deficiencies in nicotinamide adenine dinucleotide (NAD+) and glutathione metabolism. Here it is investigated if administration of a mixture of combined metabolic activators (CMAs) consisting of glutathione and NAD+ precursors can restore metabolic function and thus aid the recovery of COVID‐19 patients. CMAs include l‐serine, N‐acetyl‐l‐cysteine, nicotinamide riboside, and l‐carnitine tartrate, salt form of l‐carnitine. Placebo‐controlled, open‐label phase 2 study and double‐blinded phase 3 clinical trials are conducted to investigate the time of symptom‐free recovery on ambulatory patients using CMAs. The results of both studies show that the time to complete recovery is significantly shorter in the CMA group (6.6 vs 9.3 d) in phase 2 and (5.7 vs 9.2 d) in phase 3 trials compared to placebo group. A comprehensive analysis of the plasma metabolome and proteome reveals major metabolic changes. Plasma levels of proteins and metabolites associated with inflammation and antioxidant metabolism are significantly improved in patients treated with CMAs as compared to placebo. The results show that treating patients infected with COVID‐19 with CMAs lead to a more rapid symptom‐free recovery, suggesting a role for such a therapeutic regime in the treatment of infections leading to respiratory problems.

【 授权许可】

Unknown